FDA Elimination Of Neoral "Microemulsion" Designation Disputed By Novartis
Executive Summary
FDA's elimination of "microemulsion" dosage forms is unlawful, Novartis contended in a Feb. 11 lawsuit challenging FDA's approval of SangStat's generic version of Neoral (cyclosporine).
You may also be interested in...
Novartis Offers Gengraf Patients Transition Monitoring If Generic Is Pulled
Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted
Novartis Offers Gengraf Patients Transition Monitoring If Generic Is Pulled
Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted
Abbott/SangStat May Launch Oral Solution Gengraf To Replace SangCya
SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.